Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant

Copyright © 2022 by The American Association of Immunologists, Inc..

Although the immunological memory produced by BNT162b2 vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well studied and established, further information using different racial cohorts is necessary to understand the overall immunological response to vaccination. We evaluated memory B and T cell responses to the severe acute respiratory syndrome coronavirus 2 spike protein before and after the third booster using a Japanese cohort. Although the Ab titer against the spike receptor-binding domain (RBD) decreased significantly 8 mo after the second vaccination, the number of memory B cells continued to increase, whereas the number of memory T cells decreased slowly. Memory B and T cells from unvaccinated infected patients showed similar kinetics. After the third vaccination, the Ab titer increased to the level of the second vaccination, and memory B cells increased at significantly higher levels before the booster, whereas memory T cells recovered close to the second vaccination levels. In memory T cells, the frequency of CXCR5+CXCR3+CCR6- circulating follicular Th1 was positively correlated with RBD-specific Ab-secreting B cells. For the response to variant RBDs, although 60-80% of memory B cells could bind to the omicron RBD, their avidity was low, whereas memory T cells show an equal response to the omicron spike. Thus, the persistent presence of memory B and T cells will quickly upregulate Ab production and T cell responses after omicron strain infection, which prevents severe illness and death due to coronavirus disease 2019.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:209

Enthalten in:

Journal of immunology (Baltimore, Md. : 1950) - 209(2022), 11 vom: 01. Dez., Seite 2104-2113

Sprache:

Englisch

Beteiligte Personen:

Mise-Omata, Setsuko [VerfasserIn]
Ikeda, Mari [VerfasserIn]
Takeshita, Masaru [VerfasserIn]
Uwamino, Yoshifumi [VerfasserIn]
Wakui, Masatoshi [VerfasserIn]
Arai, Tomoko [VerfasserIn]
Yoshifuji, Ayumi [VerfasserIn]
Murano, Kensaku [VerfasserIn]
Siomi, Haruhiko [VerfasserIn]
Nakagawara, Kensuke [VerfasserIn]
Ohyagi, Masaki [VerfasserIn]
Ando, Makoto [VerfasserIn]
Hasegawa, Naoki [VerfasserIn]
Saya, Hideyuki [VerfasserIn]
Murata, Mitsuru [VerfasserIn]
Fukunaga, Koichi [VerfasserIn]
Namkoong, Ho [VerfasserIn]
Lu, Xiuyuan [VerfasserIn]
Yamasaki, Sho [VerfasserIn]
Yoshimura, Akihiko [VerfasserIn]

Links:

Volltext

Themen:

BNT162 Vaccine
Journal Article
Research Support, Non-U.S. Gov't
Spike protein, SARS-CoV-2

Anmerkungen:

Date Completed 29.11.2022

Date Revised 21.04.2023

published: Print

Citation Status MEDLINE

doi:

10.4049/jimmunol.2200525

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM349399425